Business Context and Reporting Period
This Form 8-K is a current report filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc., which is the target of a proposed merger) on January 15, 2025. The filing details the immediate effectuation of a reverse stock split of the company's common stock, a move connected to a proposed merger with Kalaris Therapeutics, Inc.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on capital structure changes.
Material Changes
- Reverse Stock Split: Effective 4:05 p.m. Eastern Time on January 15, 2025, AlloVir executed a 1-for-23 reverse stock split of its issued and outstanding common stock.
- Share Reclassification: Every 23 shares of common stock were automatically reclassified into one new share.
- Fractional Shares: No fractional shares were issued; holders entitled to fractions received cash payments based on the closing sales price on January 15, 2025.
- Trading Adjustments: Trading on The Nasdaq Capital Market resumed on a split-adjusted basis on January 16, 2025, under the existing symbol ALVR with a new CUSIP number (019818202).
- Equity Awards: Proportionate adjustments were made to exercise prices and share counts for outstanding equity awards.
Guidance, Outlook, and Risks
Merger Context: The reverse stock split is being conducted in connection with a proposed merger between AlloVir and Kalaris Therapeutics, Inc. The filing explicitly states that this communication is not a substitute for the Form S-4 or Proxy Statements regarding the merger.
Investor Action: Investors are urged to read the Form S-4 and Proxy Statements in their entirety before making voting decisions, as they contain critical information about the proposed merger and the reverse stock split.
Risks/Contingencies: The filing notes that no offer or solicitation of securities is being made in jurisdictions where such actions would be unlawful without registration. The Board retains the authority to abandon the amendment, though the split has already been effected.
Important Facts for Investors to Verify
- Verify the new CUSIP number (019818202) for post-split trading.
- Confirm the cash payment received for any fractional shares based on the January 15, 2025 closing price.
- Review the Form S-4 and Proxy Statements for details on the proposed merger with Kalaris Therapeutics, Inc.
- Check adjusted exercise prices and share counts for any held equity awards.
- Note that the filing entity is AlloVir, Inc., despite the metadata reference to Kalaris Therapeutics.